Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 5/20 | 0.53 |
| ▸ | METTL3 | Q86U44 | 11/20 | 0.50 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALB | P02768 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18571875 | 1.00 | ADK (0.53) | ADKMETTL3RAPGEF3PRMT5ALDH1A1 | |
| SCHEMBL19120374 | 0.87 | ADK (0.54) | ADKMETTL3PRMT5ALDH1A1LMNA | |
| SCHEMBL10266132 | 0.87 | ADK (0.54) | ADKMETTL3PRMT5ALDH1A1LMNA | |
| SCHEMBL19343834 | 0.86 | ADK (0.52) | ADKMETTL3ALDH1A1LMNAALB | |
| SCHEMBL12993150 | 0.86 | ADK (0.53) | ADKPRMT5ALDH1A1LMNAALB | |
| SCHEMBL13065176 | 0.86 | ADK (0.53) | ADKPRMT5ALDH1A1LMNAALB | |
| SCHEMBL20938334 | 0.86 | METTL3 (0.43) | ADKMETTL3PRMT5ALDH1A1LMNA | |
| SCHEMBL13349028 | 0.86 | ADK (0.53) | ADKPRMT5ALDH1A1LMNAALB | |
| SCHEMBL20938430 | 0.84 | PRMT5 (0.46) | ADKMETTL3PRMT5ALDH1A1LMNA | |
| SCHEMBL10265019 | 0.84 | ADK (0.54) | ADKALDH1A1LMNAALBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219496-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | disclosed |
| WO-2019076633-A1 | NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF PARASITIC INFECTIONS | UNIVERSITEIT GENT (BE) | 2019-04-25 | — | — | WO | disclosed |
| WO-2017032840-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | WO | disclosed |
| US-20100297079-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION | CHIMERIX, INC. (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297079-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION | HAVCR2, EIF2AK2, OAT | ADK 2308/4885METTL3 550/4885RAPGEF3 4028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.